Document:

EX-4.18

 Exhibit 4.18 

2018 FREE SHARE PLAN 

REGULATION 
  

							
	 	  	 TABLE OF CONTENTS 
	  	 	 
	1.	  	Definitions	  	 	3	 
	2.	  	Shares Covered by Regulation 2018	  	 	4	 
	3.	  	Administration of Regulation 2018	  	 	5	 
	4.	  	Limitations	  	 	5	 
	5.	  	Term of Regulation 2018	  	 	6	 
	6.	  	Free Shares Award	  	 	6	 
	7.	  	Criteria and Conditions of Award	  	 	6	 
	8.	  	Calendar for the Free Shares Award	  	 	7	 
	9.	  	Adjustments	  	 	10	 
	10.	  	Intervening Transactions	  	 	10	 
	11.	  	Amendment of Regulation 2018 – Management	  	 	10	 
	12.	  	Tax and Social Security Rules	  	 	11	 
	13.	  	Specific Restrictions and Information	  	 	11	 
	14.	  	Responsibility of the Company	  	 	12	 
	15.	  	Applicable Law, Jurisdiction	  	 	12	 

 2018 FREE SHARE PLAN 

REGULATION 2018 
 Based on the
authorization granted by the combined general meeting on June 22, 2018 the Board of Directors of DBV Technologies (the “Company”) decided, at its meeting on June 22,2018 in accordance with Articles L.225-197-1 to L.225-197-5 of the Commercial Code, to adopt a regulation (“2018 FREE
SHARE Regulation”) for the purpose of awarding free shares in the Company to Eligible Persons (as defined below), which bylaw will govern the awarding of free shares, and the terms and conditions of which are set out below. 

1. DEFINITIONS 
  

	(a)	 “Share” means a share of the Company; 

 

	(b)	 “Free Share Allocation” means the free share allocation on the terms and conditions set out in
Regulation 2018; 

  
 3 

	(c)	 “Shareholders’ Authorization” means the authorization to allocate shares free of charge
granted to the Board of Directors by the shareholders of the Company at the extraordinary combined general meeting on June 22, 2018; 

  

	(d)	 “Beneficiary” means an Eligible Person to whom at least one Share has been allocated free of
charge in accordance with Regulation 2018; 

  

	(e)	 “Change of Control” means the completion of any transaction that has the effect of bringing
about a change in the Control of the Company. The term “Control” has the meaning given to it in Article L.233-3 of the Commercial Code; 

 

	(f)	 “Award Date” means the date on which the Board of Directors grants the Free Share Allocation
and constitutes the date on which the Acquisition Period commences; 

  

	(g)	 “Eligible Person” means an officer (President, director general, or deputy director general of
the Company) or employee of the Company or an Affiliate Company who meets the conditions set out in Articles L.225-197-1 and L.225-197-2 of the Commercial Code and satisfies the conditions and criteria for the award established by the Board of Directors in its decision of June 22, 2018 and set out in Article 7 of Regulation
2018; 

  

	(h)	 “Manager” means the Board of Directors of the Company that administers Regulation 2018 in
accordance with Article 3 of Regulation 2018; 

  

	(i)	 “Disability” means a disability on the part of the Beneficiary that corresponds to
classification in the second or third category provided in Article L.341-4 of the Social Security Code; 

  

	(J)	 “Regulation 2018” means this 2018 Free Share Plan as adopted by the Manager on June 22,
2018. 

  
 4 

	(k)	 “Employee” means a natural person who is employed by the Company (or any Affiliated Company)
and is subject to the power of control and direction of the employer entity in the performance and conduct of the work to be carried out; 

  

	(l)	 “Company” means DBV Technologies, a limited company incorporated under French law;

  

	(m)	 “Affiliated Company” means a company that meets the criteria set out in Article L.225-197-2 of the Commercial Code: 

  

	 	•	 	 companies of which at least ten percent (10%) of the capital or voting rights are held, directly or
indirectly, by the Company; 

  

	 	•	 	 companies that hold, directly or indirectly, at least ten percent (10%) of the capital or voting rights of
the Company; and 

  

	 	•	 	 companies of which at least fifty percent (50%) of the capital or voting rights are held, directly or
indirectly, by a company that itself holds, directly or indirectly, at least fifty percent (50%) of the capital or voting rights of the Company. 

  

	2.	 SHARES COVERED BY REGULATION 2018 

All Free shares plan based on the authorization granted by the combined general meeting on June 22, 2018 to the Board of Directors of DBV Technologies.

 The total number of Free shares according with the Shareholder’s authorization shall not exceed 4.5% of the share capital on the date of
June 22, 2018, Meeting (i.e. 1,350,285 shares). 
  

	3.	 ADMINISTRATION OF REGULATION 2018 

 

	 	(a)	 Administration 

Regulation 2018 will be administered by the Manager. 

  
 5 

	 	(b)	 Powers of the Manager 

Within the limits of the Commercial Code, the Shareholders’ Authorization and Regulation 2018, the Manager will have discretion to: 

 

	 	i.	 determine the Eligible Persons to whom Shares will be allocated free of charge and decide the number of bonus
Shares to be awarded to each of them; 

  

	 	ii.	 determine the terms and conditions of any Free Share Allocation; 

 

	 	iii.	 analyze and interpret the terms of Regulation 2018; 

 

	 	iv.	 decide to change or cancel any rule in Regulation 2018, within the limits prescribed by law;

  

	 	v.	 make any necessary or advisable decision in the course of executing Regulation 2018. 

 

	 	(c)	 Effects of Decisions of the Manager 

The decisions and interpretations of the Manager are final and binding on all Beneficiaries. 

 

	4.	 LIMITATIONS 

 

	(a)	 The Shares allocated free of charge are governed by Articles L.225-197-1 to L.225-197-5 of the Commercial Code. They do not in any way constitute a component of the contract of employment
or office or compensation of the Beneficiary. 

 Neither Regulation 2018 nor any Share allocated free of charge confers a right on the
Beneficiary to remain in employment in the Company or an Affiliated Company, or in office in the Company. Moreover, they do not in any event limit the right that the Beneficiary, the Company, or an Affiliated Company, as the case may be, may have to
terminate such employment or office in any circumstance, with or without cause. 

  
 6 

	(b)	 In accordance with Article
L.225-197-1 of the Commercial Code, no Share may be allocated free of charge to an Eligible Person who, at the time of allocation the Share, directly holds more than 10%
of the capital of the Company, or for whom the effect of the award would be to increase his/her participation to more than 10% of the capital of the Company. 

 

	5.	 TERM OF REGULATION 2018 

Relying on the authorization and powers granted to it by the General Shareholders’ Meeting on June 22, 2018, the Board of Directors, in its decision
dated June 22, 2018 decided to adopt Regulation 2018, which came into effect on June 22, 2018. Unless it is cancelled early in accordance with the provisions of Article 11, Regulation 2018 will remain in effect until the expiration of the
Retention Period for the last Share allocated free of charge. 
  

	6.	 BONUS SHARE AWARD 

 

	 	(a)	 Decision to award 

The Manager will decide during Board of Directors meetings to allocate free shares to the new DBV Technologies S.A.’s employees according a fixed ratio.

  

	 	(b)	 Award of Shares and Acceptance by Beneficiaries 

Each Eligible Person will be informed of the Free Share Allocation by a notification letter setting out, in particular, (i) the number of Shares allocated
free of charge to him/her, (ii) the term of the Acquisition Period, (iii) the term of the Retention Period, (iv) the conditions and criteria to be met in order for the award to become definitive at the end of the Acquisition Period,
and (v) any obligation imposed on him/her. A copy of Regulation 2018 will be attached to the notification letter. A sample notification letter is set out in an Appendix to Regulation 2018. 

The notification letter will be sent to the Beneficiary by registered mail with acknowledgement of receipt or delivered by hand to the Beneficiary by the
Manager or by any duly authorized person, and the Beneficiary will acknowledge receipt. 
 In the event that the Beneficiary would like to take up the Free
Share Allocation, he/she must make his/her acceptance known to the Company by sending the second copy of the notification of the Free Share Allocation to the Company, addressed to the Manager, by registered mail with acknowledgement of receipt or by
hand, signed by him/her under the notation “Good for acceptance,” within thirty (30) days of receipt of the notification of the Free Share Allocation. 

Acceptance of Regulation 2018 by a Beneficiary constitutes acceptance of all of its terms. 

  
 7 

	7.	 CRITERIA AND CONDITIONS OF AWARD 

The Share award presumes that each Beneficiary meets the following conditions and criteria, which were decided General Shareholders’ Meeting on
June 22, 2018 and by the Board of Directors in its decision dated June 22, 2018, and which have been brought to the attention of the Beneficiaries by individual letter: 

 

	 	•	 	 the Beneficiary must continue to be an Eligible Person throughout the entire Acquisition Period.

  

	 	•	 	 The definitive allocation of the free shares will only occur at the later of the following two dates, subject to
the presence requirement set out below: 

 (i) expiry of the current vesting period as from their initial allocation; and

 (ii) approval of Viaskin Peanut by the US Food and Drug Administration (US FDA) (performance condition). 

 

	8.	 CALENDAR FOR THE BONUS SHARE AWARD 

 

	 	(a)	 Acquisition Period 

The Free Share Allocation to Beneficiaries will become definitive only at the end of an Acquisition Period of a minimum of one (1) year from the
allocation date, or, on the terms set out in Article 7, on the condition that, throughout the entire Acquisition Period, the Beneficiary has continued to be an Eligible Person. 

In accordance with Article L.225-197-3 of the Commercial Code, the rights
resulting from the Free Share Allocation may not be assigned or transferred by any method whatsoever until the end of the Acquisition Period. However, in the event of the death of the beneficiary, his/her heirs may request that the shares be awarded
within six months from the date of death. 
 The definitive award is subject to an attendance requirement that is determined in accordance with the precise
terms and conditions below. In order to be Eligible, beneficiaries must therefore have a relationship with the Company or an Affiliated Company, throughout the entire Acquisition Period, by virtue of an office and/or a contract of employment. 

Accordingly, in the event of resignation, voluntary or involuntary retirement, termination of the Beneficiary’s contract of employment by mutual
agreement with the company concerned, dismissal, removal, or non-renewal of the Beneficiary’s office, during the Acquisition Period, for any cause whatsoever, the Beneficiary would, unless otherwise first
decided by the Manager, lose all rights to the Free Share Allocation and could make no claim for compensation in that regard. 

  
 8 

	 	•	 	 Dismissal of the Beneficiary and/or removal and/or non-renewal of the
Beneficiary’s offices during the Acquisition Period: 

  

	 	•	 	 If the Beneficiary has only a contract of employment, the loss of the right to the Free
Share Allocation will take place on the date of receipt (or first presentation) of the letter of notification of dismissal, notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by the beneficiary
of his/her dismissal and/or the reasons for the dismissal, and (iii) any judicial decision setting aside the dismissal. 

  

	 	•	 	 If the Beneficiary has only an office, the loss of the right to the Free Share Allocation will take place
on the date of the meeting of the corporate body at which the removal was decided or the Beneficiary was replaced as the office holder, if the beneficiary is a member of it, and if the Beneficiary is not a member of it, as of the date on which
notice of the decision is received by the Beneficiary, notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by the beneficiary of his/her removal and/or the reasons for the removal, and
(iii) any judicial decision setting aside the removal. 

  

	 	•	 	 If the Beneficiary has both a contract of employment and an office and, in the event of the
simultaneous or successive loss of both positions, the loss of the right to the Free Share Allocation will take place on the date of receipt of the latter of the two notices referred to in the two preceding paragraphs. 

 

	 	•	 	 Resignation during the Acquisition Period: 

In the event of the resignation of the Beneficiary from his/her position as an employee, if the Beneficiary is an employee only, or as an officer, if the
Beneficiary is an officer only, or in the event of simultaneous or successive resignation from his/her position as an employee and as an officer, in the event that the Beneficiary holds both positions at the same time, the loss of the right to the
Free Share Allocation will take place: 
  

	 	•	 	 if the Beneficiary is only an employee or an officer, on the date of receipt by the Company of the
Beneficiary’s letter of resignation or on the date on which it is delivered by hand to an authorized representative of the Company that employs him/her; and 

  
 9 

	 	•	 	 if the Beneficiary holds positions as both an employee and an officer, the date of receipt by the Company
of the first of the letters of resignation, or the date on which it is delivered by hand to an authorized representative of the Company that employs him/her. 

notwithstanding any notice requirement, whether or not it has been given. 
  

	 	•	 	 Mutual agreement between the Beneficiary and the company that employs him/her during the Acquisition Period:

 In the event of termination of the contract of employment by mutual agreement between the Beneficiary and the company that employs
him/her (including in the case of contractual termination) if the Beneficiary is only an employee, or in the case of termination of the contract of employment by mutual agreement between the Beneficiary and the company that employs him/her and the
simultaneous or successive resignation or removal from his/her office, in the event that the Beneficiary holds both positions at the same time, the Beneficiary would lose his/her right to the Free Share Allocation on the first date on which the
agreement terminating the Beneficiary’s position as an employee is signed (or on which the agreement relating to the contractual termination is made), or the date of receipt of the notification of removal from office or the date of resignation
from office. 
  

	 	•	 	 Retirement of the Beneficiary during the Acquisition Period; 

In the event that the Beneficiary retires during the Acquisition Period, the Beneficiary will lose his/her right to the Free Share Allocation on the date of
retirement. 
 However, by exception to the foregoing: 
  

	(i)	 in the event of the involuntary retirement of the Beneficiary at the initiative of the company that employs
him/her during the Acquisition Period, in accordance with the applicable statutory and regulatory requirements, the Beneficiary will retain his/her right to the Free Share Allocation, on the condition that he/she adheres to the Acquisition Period;

  

	(ii)	 in the event of the death of the Beneficiary during the Acquisition Period, his/her heirs may request the Free
Share Allocation within six (6) months of the death; 

  

	(iii)	 in the event of disability, the Beneficiary may request that the Shares be awarded within six (6) months
of the event that resulted in the disability. 

  
 10 

 It is specified that during the Acquisition Period, the Beneficiaries are not the owners of the Shares and
have no shareholder’s rights. In particular, they do not have the right to dividends, the right to vote, or the right to the information communicated to shareholders attached to the Shares. 

 

	 	(b)	 Delivery of the Shares 

At the end of the Acquisition Period, the Company will, on the condition that the Beneficiary has adhered to the conditions and criteria of acquisition set out
in Article 7 above, transfer to the Beneficiary the number of Shares decided by the Board of Directors. 
 The shares awarded will immediately be treated in
the same manner as the existing shares and will carry immediate dividend rights. 
  

	 	(c)	 Share Retention Period 

The Shares must be retained by the Beneficiary throughout the Retention Period. As an exception, the shares will be freely transferable in the event of the
death or disability of the Beneficiary. 
 If the Beneficiary is an officer, he/she will be required to administer at least 10% of the Shares awarded to
him/her as registered shares until he/she ceases to hold office. 
 The Shares must be held in registered form in an account specifying that they are not
available. 
 The Beneficiary has standing as a shareholder when the Shares are definitively awarded and throughout the Retention Period and may therefore
exercise the rights attached to the bonus Shares throughout the Retention Period. 
 At the end of the Retention Period, the Shares may be freely
transferred by the Beneficiary, subject to the provisions of the Company’s articles of association and the regulations applicable to companies whose shares are listed on a regulated market. 

 

	9.	 ADJUSTMENTS 

The Manager will be the only person with authority to decide, where applicable, the conditions on which the number of bonus Shares awarded will be adjusted in
the event of transactions involving the capital of the Company in order to preserve the rights of the Beneficiaries of the said Free Share Allocations. 

  
 11 

	10.	 INTERVENING TRANSACTIONS 

 

	(a)	 Take over of control 

In the event of a takeover of control and by derogation from the provisions of Articles 7 and 8 of this regulation, the beneficiaries will remain eligible for
the allocation at the end of the vesting period, even if their employment contract and/or corporate mandate is terminated, for any reason, between the date of the takeover and the last day of the vesting period. In this specific case, the shares
will vest with no requirement to wait for the plan’s performance criteria to be met. 
  

	(b)	 Exchange of Shares 

In the event of an exchange of shares resulting from a merger or split carried out in accordance with the regulations in force during the acquisition period,
the provisions of this Article and, in particular, the above-mentioned periods, for the times remaining to run on the date of the exchange, will continue to be applicable to the rights to the award and the shares received in exchange. 

 

	11.	 AMENDMENT OF REGULATION 2018—MANAGEMENT 

 

	 	(a)	 Amendment 

The Manager may, at any time, amend the provisions of, suspend, or terminate Regulation 2018, on the condition that it is done in compliance with the law. 

 

	 	(b)	 Consequences of Amendment or Cancellation 

No amendment, alteration, suspension, or cancellation of Regulation 2018 may reduce the rights of a Beneficiary without his/her agreement, unless such
amendment results from a legislative or regulatory provision that has newly come into force or from any other provision that has executory effect and is mandatory for the Company or an Affiliated Company. 

 

	 	(c)	 Management 

The management of Regulation 2018 is assigned to the Manager. However, the Manager reserves the ability to assign the management of Regulation 2018 to any
financial institution. The Manager will inform the Beneficiaries by registered letter with acknowledgement of receipt or delivery by hand specifying the name and contact information of the financial institution chosen by the Manager to handle the
management of Regulation 2018. 

  
 12 

	12.	 TAX AND SOCIAL SECURITY RULES 

The Beneficiary will bear the cost of all taxes and mandatory deductions for which he/she is responsible under the tax regulations in force on the date on
which the taxes or deductions become payable. 
 The Beneficiary is invited to obtain advice about his/her own personal tax situation, in particular in
order to be aware of the tax and social security treatment that will apply to him/her, and the Beneficiary declares that he/she is not in any way relying on any tax or social security advice given by the Company. 

 

	13.	 SPECIFIC RESTRICTIONS AND INFORMATION 

Any person who holds shares of a company must, in general, abstain from transferring them, acquiring new shares, or giving advice concerning those shares if
he/she is in possession of information that could have a significant influence on the market price of the company that has not been made public. Persons who violate those rules may be subject to penal and financial sanctions. Those rules apply to
Eligible Persons who receive Shares. 
 We invite you to refer to the Code of Ethics adopted by the Company that is online on the Intranet. 

Moreover, in accordance with Article L.225-197-1 I of the Commercial
Code, the Shares may not be assigned or transferred after the expiration of the Retention Period: 
  

	 	•	 	 within ten (10) trading sessions preceding and three (3) trading sessions following the date on which
the consolidated accounts or, if none, the annual accounts are made public; 

  

	 	•	 	 within the time between the date on which the corporate bodies of the Company have knowledge of information that,
if it were made public, could have a significant impact on the market price of the Company’s shares, and the date ten (10) trading sessions before the date on which the information is made public. 

A calendar of publications is distributed annually and is accessible online on the Intranet. 

In accordance with the provisions of Article L.621-18-2 of the Monetary and
Financial Code, the transfer of shares by an officer or any person who has, within the Company, (i) the power to make management decisions concerning the Company’s activities and strategy, and (ii) regular access to privileged
information concerning the Company directly or indirectly requires that information be provided to the Autorité des Marchés Financiers [financial markets authority], with a copy to the Company, within the time allowed by the
regulations in force. 

  
 13 

	15.	 LIABILITY OF THE COMPANY 

The Company and its Affiliated Companies may not, in any way, be held liable if, for any reason whatsoever not attributable to the Company or its Affiliated
Companies, a Beneficiary was not able to acquire the Shares awarded to him/her. 
  

	16.	 APPLICABLE LAW, JURISDICTION 

Regulation 2018 is governed by French law and in particular by the provisions of Articles
L.225-197-1 et seq. of the Commercial Code. 
 Any dispute relating
to Regulation 2018 will be within the exclusive jurisdiction of the court of competent jurisdiction subject to the jurisdiction of the court of appeal in the place in which the head office of the Company is located. 

The Free Share Allocation under Regulation 2018 authorizes the Society, at any time, to ask the Beneficiary to comply with any legislative and regulatory
provision governing the Shares. 

*                *       
         * 
 * 

  
 14 

 APPENDIX 

SAMPLE NOTIFICATION LETTER CONCERNING DBV TECHNOLOGIES FREE 

SHARE ALLOCATION 
  

	
	 Montrouge, [date]

	
	 [Name of Beneficiary]

 Dear Sir/Madam: 
 We are
pleased to inform you that the Board of Directors of the Company has decided to allocate free shares of the Company to you in accordance with the provisions of the regulation governing the free share plan, a copy of which is attached in an Appendix
(“Regulation 2018”). 
 The terms that are not defined in this letter and that are capitalized have the meaning assigned to them in
Regulation 2018. 
 These free Shares have been awarded under the provisions of Articles L.225-197-1 to L.225-197-5 of the Commercial Code. 

Under the decision of the Board of Directors, you were awarded [    ] ([    ]) free shares of the Company, on
[                ], on the terms set out below. 
  

	1.	 Acquisition Period and conditions 

The definitive allocation of the free shares will only occur at the later of the following two dates, subject to the presence requirement set
out below: 
 (i) expiry of the current vesting period as from their initial allocation; and 

(ii) approval of Viaskin Peanut by the US Food and Drug Administration (US FDA) (performance condition). 

 

	2.	 Conditions and criteria of allocation 

The Free Share Allocation assumes that during the Acquisition Period referred to above, you will meet the following conditions and criteria: 

You must, throughout the Acquisition Period, have a relationship with the Company or an Affiliated Company under an office and/or a contract of employment.

 In the event of resignation, voluntary or involuntary retirement, termination of the contract of employment by mutual agreement, dismissal, removal, or
termination of the office, during the Acquisition Period, for any reason whatsoever, you will lose all right to the Free Share Allocation and may claim no compensation in that regard. 

  
 15 

 In the event of resignation, the loss of the right to the Free Share Allocation will occur on the date of
receipt by the Company or the Affiliated Company concerned of your letter of resignation or on the date of delivery by hand of the letter to an authorized representative of the company that employs you, notwithstanding any notice requirement,
whether or not it has been given. 
 In the event of dismissal or removal, the loss of the right to the Free Share Allocation will occur on the date of
receipt (or first presentation) of the letter of notification of dismissal or removal, notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by you of your dismissal and/or the reasons for the
dismissal, and (iii) any judicial decision setting aside the dismissal. 
 However, by exception to the foregoing, 

 

	(i)	 in the event of retirement during the Acquisition Period, you will retain your right to the Free Share
Allocation; 

  

	(ii)	 in the event of death during the Acquisition Period, your heirs may request the Free Share Allocation within
six (6) months of the date of your death. 

  

	(iii)	 in the event disability during the Acquisition Period, you may request the Free Share Allocation within six
(6) months of the date of your disability. 

  

	(iv)	 In the event of a takeover of control within the meaning of Article L.
233-3 of the French Commercial Code of DBV Technologies by any person acting alone or in concert with other persons, the beneficiaries will remain eligible for the allocation at the end of the vesting period,
even if their employment contract and/or corporate mandate is terminated, for any reason, between the date of the takeover and the last day of the vesting period. In this specific case, the shares will vest with no requirement to wait for the
plan’s performance criteria to be met. 

  

	3.	 Retention Period 

On the final allocation of the Shares, you agree to retain them during the Retention Period of two years. 

Accordingly, the Shares awarded must be held in registered form in an account specifying that they are not available. 

  
 16 

 You will have the status of shareholder as of the final allocation of the Shares and throughout the
Retention Period, notwithstanding the retention obligation. You may therefore, throughout the Retention Period, exercise the rights attached to the Shares allocated to you and, in particular, the right of communication, the right to participate in
meetings, the right to vote, the right to dividends, and the preferential subscription right. 
 At the end of the above-mentioned Retention Period, the
Shares will become available and may, in particular, be freely transferred (subject to the abstention periods referred to in Regulation 2018). 
 Your
acceptance of the Free Share Allocation on the terms set out above constitutes acceptance of the terms of Bylaw 2018. 
 In the event that you accept the
Free Share Allocation, we would appreciate it if you would sign two copies of this notification of Free Share Allocation and keep one copy and return the other to the Company by registered letter or delivered by hand in a period of 30 days from the
receipt of this letter. Otherwise, the award will be void. 
  

	
	 Sincerely yours,

	
	 Pierre-Henri Behnamou

  

	
	 Good for acceptance

	
	 [Name of Beneficiary]

	
	 Encl.: Regulation 2018

  
 17SHARE
EXCHANGE AGREEMENT

 

This
SHARE EXCHANGE AGREEMENT (this “Agreement”), dated as of March __, 2019, is entered into by and between GSRX
Industries Inc., a Nevada corporation (the “Company”), and Chemesis International Inc., a British Columbian
Corporation (“CSI”). Each of the parties to this Agreement is individually referred to herein as a “Party”
and collectively as the “Parties.”

 

WHEREAS,
the Company has agreed to issue an aggregate of 11,666,998 restricted shares of its common stock, par value $0.001 per share,
(the “GSRX Shares”) to CSI, in exchange (the “Exchange”) for 7,291,874 restricted shares
of common stock of CSI (the “CSI Shares”) to be issued to GSRX. The “GSRX Shares” and CSI
Shares are collectively referred to as the “Exchange Securities.”

 

WHEREAS,
the respective Board of Directors of the Company and CSI have determined that it is desirable to effectuate the Exchange.

 

NOW
THEREFORE, for good and valuable consideration the receipt and sufficiency is hereby acknowledged, the Parties hereto intending
to be legally bound hereby agree as follows:

 

ARTICLE
I

The Exchange

 

SECTION
1.01. Exchange. At the Closing (as defined in Section 1.02 below), the Company shall sell, transfer, convey, assign and
deliver to CSI the GSRX Shares free and clear of all Liens, and the Company shall, simultaneously therewith, deliver to CSI a
certificate representing the GSRX Shares. Additionally at the Closing, CSI shall sell, transfer, convey, assign and deliver to
GSRX the CSI Shares free and clear of all Liens, and CSI shall, simultaneously therewith, deliver to GSRX a certificate representing
the CSI Shares. The Parties shall have the right to request that the respective GSRX Shares and CSI shares be issued in book entry
form.

 

SECTION
1.02. Closing. The closing (the “Closing”) of the transactions contemplated by this Agreement (the “Transactions”)
shall take place on the Effective Date (as defined below) at such location to be determined by the Company and CSI, commencing
upon the satisfaction or waiver of all conditions and obligations of the Parties to consummate the Transactions contemplated hereby,
as more fully set forth in Article V herein (other than conditions and obligations with respect to the actions that the respective
Parties will take at Closing) or such other date and time as the Parties may mutually determine (the “Closing Date”).
For purposes hereof, the effective date of the Closing (the “Effective Date”) shall be at the time of satisfaction,
in full, of the conditions set forth in Article V herein.

 

SECTION
1.03. Mutual Leak Out. Beginning six (6) months after the Effective Date, the Company shall be able to sell up to 1,215,313
of the CSI Shares and CSI shall be able to sell 1,944,500 of the GSRX Shares every six (6) months, subject to compliance with
any applicable securities laws and stock exchange rules.

 

    	 

    	 

    

 

ARTICLE
II

Representations and Warranties of the Company

 

The
Company hereby represents and warrants to CSI as follows:

 

SECTION
2.01. Organization, Standing and Power. The Company is duly organized, validly existing and in good standing under the
laws of Nevada and has the corporate power and authority and possesses all governmental franchises, licenses, permits, authorizations
and approvals necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its businesses as
presently conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which, individually
or in the aggregate, has not had and would not reasonably be expected to have a material adverse effect on the Company, a material
adverse effect on the ability of the Company to perform its obligations under this Agreement or on the ability of the Company
to consummate the Transactions (a “Company Material Adverse Effect”). The Company is duly qualified to do business
in each jurisdiction where the nature of its business or its ownership or leasing of its properties make such qualification necessary,
except where the failure to so qualify would not reasonably be expected to have a Company Material Adverse Effect. The Company
has delivered to CSI true and complete copies of the organization documents of the Company in effect as of the date of this Agreement
(the “Company Charter Documents”).

 

SECTION
2.02. Capital Structure. The authorized share capital of the Company consists of 100,000,000 shares of common stock with
46,961,134 shares issued and outstanding immediately prior to the execution of this
Agreement, and 1,000 shares of preferred stock authorized, with 1,000 shares currently issued and outstanding immediately prior
to the execution of this Agreement. All outstanding shares of the Company are duly authorized, validly issued, fully paid and
non-assessable and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive
right, subscription right or any similar right under any provision of the applicable corporate laws of its state of incorporation,
the Company Charter Documents or any Contract (as defined in Section 2.10) to which the Company is a party or otherwise bound.
Other than as publicly disclosed, there are no bonds, debentures, notes or other indebtedness of the Company having the right
to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which holders of Interests
may vote (“Voting Company Debt”). The amount of outstanding options and warrants issued by the Company is as
set forth in the Company’s public disclosure record.

 

SECTION
2.03. Authority; Execution and Delivery; Enforceability. The Company has all requisite corporate power and authority to
execute and deliver this Agreement and to consummate the Transactions. The execution and delivery by the Company of this Agreement
and the consummation by the Company of the Transactions have been duly authorized and approved by the Board of Directors of the
Company and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement and the Transactions.
When executed and delivered, this Agreement will be enforceable against the Company in accordance with its terms, subject to bankruptcy,
insolvency and similar laws of general applicability as to which the Company is subject.

 

SECTION
2.04. No Conflicts; Consents.

 

(a)
The execution and delivery by the Company of this Agreement does not, and the consummation of the Transactions and compliance
with the terms hereof and thereof will not, conflict with, or result in any violation of or default (with or without notice or
lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or to loss
of a material benefit under, or result in the creation of any Lien upon any of the properties or assets of the Company under any
provision of (i) the Company Charter Documents, (ii) any material contract, lease, license, indenture, note, bond, agreement,
permit, concession, franchise or other instrument (a “Contract”) to which the Company is a party or by which
any of their respective properties or assets is bound or (iii) any material judgment, order or decree (“Judgment”)
or material Law applicable to the Company or its properties or assets, other than, in the case of clauses (ii) and (iii) above,
any such items that, individually or in the aggregate, have not had and would not reasonably be expected to have a Company Material
Adverse Effect.

 

    	2

    	 

    

 

(b)
No Consent of, or registration, declaration or filing with, or permit from, any Governmental Entity is required to be obtained
or made by or with respect to the Company in connection with the execution, delivery and performance of this Agreement or the
consummation of the Transactions, other than the (A) filing with the Securities and Exchange Commission of reports under Sections
13 and 16 of the Exchange Act, and (B) filings under state “blue sky” laws, as each may be required in connection
with this Agreement and the Transactions

 

SECTION
2.05. Taxes.

 

(a)
Other than as set forth in Schedule 2.05, the Company has timely filed, or has caused to be timely filed on its behalf, all Tax
Returns required to be filed by it, and all such Tax Returns are true, complete and accurate, except to the extent any failure
to file or any inaccuracies in any filed Tax Returns, individually or in the aggregate, have not had and would not reasonably
be expected to have a Company Material Adverse Effect. All Taxes shown to be due on such Tax Returns, or otherwise owed, have
been timely paid, except to the extent that any failure to pay, individually or in the aggregate, has not had and would not reasonably
be expected to have a Company Material Adverse Effect. There are no unpaid taxes in any material amount claimed to be due by the
taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.

 

(b)
There are no Liens for Taxes (other than for current Taxes not yet due and payable) on the assets of the Company. The Company
is not bound by any agreement with respect to Taxes.

 

(c)
If applicable, the Company has established an adequate reserve reflected on its financial statements for all Taxes payable by
the Company (in addition to any reserve for deferred Taxes to reflect timing differences between book and Tax items) for all Taxable
periods and portions thereof through the date of such financial statements. No deficiency with respect to any Taxes has been proposed,
asserted or assessed against the Company, and no requests for waivers of the time to assess any such Taxes are pending, except
to the extent any such deficiency or request for waiver, individually or in the aggregate, has not had and would not reasonably
be expected to have a Company Material Adverse Effect.

 

(d)
For purposes of this Agreement:

 

“Taxes”
includes all forms of taxation, whenever created or imposed, and whether of the United States or elsewhere, and whether imposed
by a local, municipal, governmental, state, foreign, federal or other Governmental Entity, or in connection with any agreement
with respect to Taxes, including all interest, penalties and additions imposed with respect to such amounts.

 

“Tax
Return” means all federal, state, local, provincial and foreign Tax returns, declarations, statements, reports, schedules,
forms and information returns and any amended Tax return relating to Taxes.

 

SECTION
2.06. ERISA Compliance; Excess Parachute Payments. The Company does not, and since its inception never has, maintained,
or contributed to any “employee pension benefit plans” (as defined in Section 3(2) of ERISA), “employee welfare
benefit plans” (as defined in Section 3(1) of ERISA) or any other Company Benefit Plan for the benefit of any current or
former employees, consultants, officers or directors of the Company.

 

    	3

    	 

    

 

SECTION
2.07. Litigation. There is no action, suit, inquiry, notice of violation, proceeding (including any partial proceeding
such as a deposition) or investigation pending or threatened in writing against or affecting the Company, or any of its properties
before or by any court, arbitrator, governmental or administrative agency, regulatory authority whether federal, state, county,
local or foreign (“Action”) which (i) adversely affects or challenges the legality, validity or enforceability
of any of this Agreement or (ii) could, if there were an unfavorable decision, individually or in the aggregate, have or reasonably
be expected to result in a Company Material Adverse Effect. Neither the Company nor any officer thereof (in his or her capacity
as such), is or has been the subject of any Action involving a claim or violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty.

 

SECTION
2.08. Compliance with Applicable Laws. The Company is in compliance with all applicable Laws except for instances of noncompliance
that, individually and in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse
Effect. The Company has not received any written communication during the past two years from a Governmental Entity that alleges
that the Company is not in compliance in any material respect with any applicable Law. The Company is in compliance with all effective
requirements of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations thereunder, that are applicable to it,
except where such noncompliance could not have or reasonably be expected to result in a Company Material Adverse Effect. This
Section 2.08 does not relate to matters with respect to Taxes, which are the subject of Section 2.05.

 

SECTION
2.09. Brokers; Schedule of Fees and Expenses. No broker, investment banker, financial advisor or other person is entitled
to any broker’s, finder’s, financial advisor’s or other similar fee or commission in connection with the Transactions
based upon arrangements made by or on behalf of the Company.

 

SECTION
2.10. Contracts. Other than as set forth in Schedule 2.10, there are no Contracts that are material to the business, properties,
assets, condition (financial or otherwise), results of operations or prospects of the Company taken as a whole. The Company is
not in violation of or in default under (nor does there exist any condition which upon the passage of time or the giving of notice
would cause such a violation of or default under) any Contract to which it is a party or by which it or any of its properties
or assets is bound, except for violations or defaults that would not, individually or in the aggregate, reasonably be expected
to result in a Company Material Adverse Effect.

 

SECTION
2.11. Title to Properties. Except as set forth in Schedule 2.11, the Company has sufficient title to, or valid leasehold
interests in, all of its properties and assets used in the conduct of its businesses. All such assets and properties, other than
assets and properties in which the Company has leasehold interests, are free and clear of all Liens other than those Liens that,
in the aggregate, do not and will not materially interfere with the ability of the Company to conduct business as currently conducted.

 

SECTION
2.12. Additional Representations and Warranties. The Company makes the additional representations and warranties as set
forth below:

 

(a)
no securities commission, securities regulatory authority, the OTCQB or any other similar regulatory body has issued any order
preventing or suspending trading of any securities of the Company, no such proceeding is, to the knowledge of the Company, pending,
contemplated or threatened, and the Company is not in default of any material requirement of Applicable United States Securities
Laws (as defined below);

 

(b)
the issued and outstanding Common Shares in the capital of the Company are listed and posted for trading on the OTCQB and the
GSRX Shares issuable hereunder will be listed and posted for trading on the OTCQB upon the Company complying with the usual conditions
imposed by the OTCQB with respect thereto and the Company is in material compliance with the by-laws, rules and regulations of
the OTCQB;

 

    	4

    	 

    

 

(c)
at Closing, the GSRX Shares shall be validly issued as fully paid and non-assessable shares of the Company. The GSRX Shares will
be issued to the Company on a basis that is exempt from the prospectus requirements under Applicable United States Securities
Laws;

 

(d)
the definitive form of share certificate evidencing the GSRX Shares has been and will be at the Closing, duly authorized, approved
and adopted by the Company and comply with all legal requirements relating thereto;

 

(e)
The Company is issuing the GSRX Shares in reliance on one or more exemptions or exclusions from the registration requirements
of the Securities Act of 1933, as amended (the “Securities Act”), including Section 4(a)(2) of the Securities Act,
Regulation D promulgated under the Securities Act and/or in reliance on Regulation S promulgated under the Securities Act

 

“Applicable
United States Securities Laws” means all applicable securities and corporate laws, rules, regulations, instruments,
notices, blanket orders, decision documents, statements, circulars, procedures and policies applicable to the Company.

 

SECTION
2.13. Labor Matters. There are no collective bargaining or other labor union agreements to which the Company is a party
or by which it is bound. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any
of the employees of the Company.

 

SECTION
2.14. Investment Company. The Company is not, and is not an affiliate of, and immediately following the Closing will not
have become, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

SECTION
2.15. Disclosure. The Company confirms that neither it nor any person acting on its behalf has provided CSI or its respective
agents or counsel with any information that the Company believes constitutes material, non-public information, except insofar
as the existence and terms of the proposed transactions hereunder may constitute such information and except for information that
will be disclosed by the Company under a current report on Form 8-K filed no later than four (4) business days after the Closing.
The Company understands and confirms that CSI will rely on the foregoing representations and covenants in effecting transactions
in the Exchanged Securities. All disclosure provided to CSI regarding the Company, its business and the Transactions, furnished
by or on behalf of the Company (including the Company’s representations and warranties set forth in this Agreement) are
true and correct and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading.

 

SECTION
2.16. Reserved.

 

SECTION
2.17. Foreign Corrupt Practices. Neither the Company, nor, to the Company’s knowledge, any officer, agent, employee
or other person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i) used any
corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity;
(ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds;
(iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made
any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government
official or employee.

 

    	5

    	 

    

 

SECTION
2.18. Transactions With Affiliates and Employees. None of the officers or directors of the Company and, to the knowledge
of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any subsidiary
(other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring
payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

 

SECTION
2.19. Application of Takeover Protections. The Company has taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other
similar anti-takeover provision under the Company’s charter documents or the laws of its state of incorporation that is
or could become applicable to the Company as a result of the Company fulfilling its obligations or exercising their rights under
this Agreement, including, without limitation, the issuance of the GSRX Shares to CSI.

 

SECTION
2.20. Listing and Maintenance Requirements. The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with the listing and maintenance requirements for continued trading of its shares of common
stock on the trading market on which such shares are currently listed or quoted. The issuance and sale of the GSRX Shares under
this Agreement does not contravene the rules and regulations of the trading market on which the Company’s securities are
currently listed or quoted, and all approvals of the stockholders of the Company, as required for the Company to issue and deliver
to CSI the GSRX Shares contemplated by this Agreement, have been obtained.

 

SECTION
2.21. Good Title. The Company has the right and authority to sell and deliver the GSRX Shares as provided herein. CSI will
receive good title to such GSRX Shares, free and clear of all liens, security interests, pledges, equities and claims of any kind,
voting trusts and other encumbrances (collectively, “Liens”).

 

SECTION
2.22. Power and Authority. All acts required to be taken by the Company in order to enter into this Agreement and to carry
out the Transactions as contemplated herein have been properly taken. This Agreement constitutes a legal, valid and binding obligation
of the Company, enforceable against it in accordance with the terms hereof.

 

SECTION
2.23. No Finder’s Fee. The Company has not created any obligation for any finder’s, investment banker’s
or broker’s fee in connection with the Transactions.

 

SECTION
2.24. Purchase Entirely for Own Account. The CSI Shares proposed to be acquired by the Company hereunder will be acquired
for investment purposes, for the Company’s account, and not with a view to the resale or distribution of any part thereof,
and the Company has no present intention of selling or otherwise distributing the CSI Shares which it will receive pursuant to
this Agreement, except in compliance with applicable securities laws.

 

SECTION
2.25. Available Information. The Company has such knowledge and experience in financial and business matters that they
are capable of evaluating the merits and risks of an investment in the CSI Shares.

 

SECTION
2.26. Non-Registration. The Company understands that the CSI Shares have not been registered under the Securities Act of
1933, as amended (the “Securities Act”) and, if issued in accordance with the provisions of this Agreement,
will be issued by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among
other things, the bona fide nature of the investment intent and the accuracy of the Parties’ representations as expressed
herein.

 

    	6

    	 

    

 

SECTION
2.27. Reserved.

 

SECTION
2.28. Accredited Investor. The Company is an “accredited investor” within the meaning of Rule 501 under the
Securities Act and the Company was not organized for the specific purpose of acquiring the CSI Shares.

 

SECTION
2.29. Acknowledgment. The Company acknowledges that it has read the representations and warranties of CSI set forth in
Article III herein and such representations and warranties are, to the best of the Company’s knowledge, true and correct
as of the date hereof.

 

SECTION
2.30. Further Acknowledgment. The Company confirms that:

 

(a)
it is not a resident of British Columbia;

 

(b)
it is purchasing the CSI Shares as principal (within the meaning of Applicable Canadian Securities Laws); and

 

(c)
the Company will comply with the securities laws requirements of its local jurisdiction with respect to its purchase of the CSI
Shares.

 

“Applicable
Canadian Securities Laws” means all applicable securities and corporate laws, rules, regulations, instruments, notices,
blanket orders, decision documents, statements, circulars, procedures and policies applicable to CSI.

 

ARTICLE
III

Representations and Warranties of CSI

 

CSI
represents and warrants as follows to the Company that:

 

SECTION
3.01. Organization, Standing and Power. CSI is duly organized, validly existing and in good standing under the laws of
British Columbia, Canada and has full corporate power and authority and possesses all governmental franchises, licenses, permits,
authorizations and approvals necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its
businesses as presently conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which,
individually or in the aggregate, has not had and would not reasonably be expected to have a material adverse effect on CSI, a
material adverse effect on the ability of CSI to perform its obligations under this Agreement or on the ability of CSI to consummate
the Transactions (a “CSI Material Adverse Effect”). CSI is duly qualified to do business in each jurisdiction
where the nature of its business or their ownership or leasing of its properties make such qualification necessary and where the
failure to so qualify would reasonably be expected to have a CSI Material Adverse Effect. CSI has delivered to the Company true
and complete copies of the Articles of Incorporation of CSI, as amended to the date of this Agreement (as so amended, the “CSI
Charter”), and the Bylaws of CSI, as amended to the date of this Agreement (as so amended, the “CSI Bylaws”).

 

SECTION
3.02. Subsidiaries; Equity Interests. Other than as set forth in its public disclosure record, CSI does not own, directly
or indirectly, any capital stock, membership interest, partnership interest, joint venture interest or other equity interest in
any person or entity and does not have the right to acquire any shares in any person or entity.

 

    	7

    	 

    

 

SECTION
3.03. Capital Structure. The authorized share capital of CSI consists of an unlimited amount of common shares with 88,522,161
shares issued and outstanding immediately prior to the execution of this Agreement. All outstanding shares of the capital
stock of CSI are duly authorized, validly issued, fully paid and non-assessable and not subject to or issued in violation of any
purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision
of the applicable corporate laws of its state of incorporation, the CSI Charter, the CSI Bylaws or any Contract to which CSI is
a party or otherwise bound. Other than as publicly disclosed, there are no bonds, debentures, notes or other indebtedness of CSI
having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which
holders of CSI’s capital stock may vote (“Voting CSI Debt”). All of the Voting CSI Debt is disclosed
and accounted for in the most recent financial statements of CSI in the Public Record. Except as set forth in Schedule 3.03, as
of the date of this Agreement, there are no options, warrants, rights, convertible or exchangeable securities, “phantom”
stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of
any kind to which CSI is a party or by which it is bound (i) obligating CSI to issue, deliver or sell, or cause to be issued,
delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible or exercisable
for or exchangeable into any capital stock of or other equity interest in, CSI or any Voting CSI Debt, (ii) obligating CSI to
issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, Contract, arrangement or undertaking
or (iii) that give any person the right to receive any economic benefit or right similar to or derived from the economic benefits
and rights occurring to holders of the capital stock of CSI. As of the date of this Agreement, there are no outstanding contractual
obligations of CSI to repurchase, redeem or otherwise acquire any shares of capital stock CSI. CSI is not a party to any agreement
granting any security holder of CSI the right to cause CSI to register shares of the capital stock or other securities of CSI
held by such security holder under the Securities Act.

 

SECTION
3.04. Authority; Execution and Delivery; Enforceability. The execution and delivery by CSI of this Agreement and the consummation
by CSI of the Transactions have been duly authorized and approved by the Board of Directors of CSI and no other corporate proceedings
on the part of CSI are necessary to authorize this Agreement and the Transactions. This Agreement constitutes a legal, valid and
binding obligation of CSI, enforceable against CSI in accordance with the terms hereof.

 

SECTION
3.05. No Conflicts; Consents.

 

(a)
The execution and delivery by CSI of this Agreement, does not, and the consummation of Transactions and compliance with the terms
hereof and thereof will not, conflict with, or result in any violation of or default (with or without notice or lapse of time,
or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or to loss of a material
benefit under, or to increased, additional, accelerated or guaranteed rights or entitlements of any person under, or result in
the creation of any Lien upon any of the properties or assets of CSI under, any provision of (i) the CSI Charter or CSI Bylaws,
(ii) any material Contract to which CSI is a party or by which any of its properties or assets is bound or (iii) subject to the
filings and other matters referred to in Section 3.05(b), any material Judgment or material Law applicable to CSI or its properties
or assets, other than, in the case of clauses (ii) and (iii) above, any such items that, individually or in the aggregate, have
not had and would not reasonably be expected to have a CSI Material Adverse Effect.

 

(b)
No Consent of, or registration, declaration or filing with, or permit from, any Governmental Entity is required to be obtained
or made by or with respect to CSI in connection with the execution, delivery and performance of this Agreement or the consummation
of the Transactions, other than the (A) filing with the Securities and Exchange Commission of reports under Sections 13 and 16
of the Exchange Act, and (B) filings under state “blue sky” laws, as each may be required in connection with this
Agreement and the Transactions.

 

    	8

    	 

    

 

SECTION
3.06. Taxes.

 

(a)
Other than as set forth in Schedule 3.06 hereof, CSI has timely filed, or has caused to be timely filed on its behalf, all Tax
Returns required to be filed by it, and all such Tax Returns are true, complete and accurate, except to the extent any failure
to file, any delinquency in filing or any inaccuracies in any filed Tax Returns, individually or in the aggregate, have not had
and would not reasonably be expected to have a CSI Material Adverse Effect. All Taxes shown to be due on such Tax Returns, or
otherwise owed, has been timely paid, except to the extent that any failure to pay, individually or in the aggregate, has not
had and would not reasonably be expected to have a CSI Material Adverse Effect.

 

(b)
There are no Liens for Taxes (other than for current Taxes not yet due and payable) on the assets of CSI. CSI is not bound by
any agreement with respect to Taxes.

 

(c)
If applicable, CSI has established an adequate reserve reflected on its financial statements for all Taxes payable by CSI (in
addition to any reserve for deferred Taxes to reflect timing differences between book and Tax items) for all Taxable periods and
portions thereof through the date of such financial statements. No deficiency with respect to any Taxes has been proposed, asserted
or assessed against CSI, and no requests for waivers of the time to assess any such Taxes are pending, except to the extent any
such deficiency or request for waiver, individually or in the aggregate, has not had and would not reasonably be expected to have
a CSI Material Adverse Effect.

 

SECTION
3.07. ERISA Compliance; Excess Parachute Payments. CSI does not, and since its inception never has, maintained, or contributed
to any “employee pension benefit plans” (as defined in Section 3(2) of ERISA), “employee welfare benefit plans”
(as defined in Section 3(1) of ERISA) or any other CSI Benefit Plan for the benefit of any current or former employees, consultants,
officers or directors of CSI.

 

SECTION
3.08. Litigation. There is no Action which (i) adversely affects or challenges the legality, validity or enforceability
of any of this Agreement or (ii) could, if there were an unfavorable decision, individually or in the aggregate, have or reasonably
be expected to result in a CSI Material Adverse Effect. Neither CSI nor any director or officer thereof (in his or her capacity
as such), is or has been the subject of any Action involving a claim or violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty.

 

SECTION
3.09. Compliance with Applicable Laws. CSI is in compliance with all applicable Laws, except for instances of noncompliance
that, individually and in the aggregate, have not had and would not reasonably be expected to have a CSI Material Adverse Effect.
CSI has not received any written communication during the past two years from a Governmental Entity that alleges that CSI is not
in compliance in any material respect with any applicable Law. This Section 3.09 does not relate to maters with respect to Taxes,
which are the subject of 3.06.

 

SECTION
3.10. Additional Canadian Representations and Warranties. CSI makes the additional representations and warranties as set
forth below:

 

(a)
no securities commission, securities regulatory authority, the Canadian Securities Exchange (the “CSE”) or
any other similar regulatory body has issued any order preventing or suspending trading of any securities of CSI, no such proceeding
is, to the knowledge of CSI, pending, contemplated or threatened, and CSI is not in default of any material requirement of Applicable
Canadian Securities Laws;

 

    	9

    	 

    

 

(b)
the issued and outstanding Common Shares in the capital of CSI are listed and posted for trading on the CSE and the CSI Shares
issuable hereunder will be listed and posted for trading on the CSE upon CSI complying with the usual conditions imposed by the
CSE with respect thereto and CSI is in material compliance with the by-laws, rules and regulations of the CSE;

 

(c)
at Closing, the CSI Shares shall be validly issued as fully paid and non-assessable shares of CSI. The CSI Shares will be issued
to the Company on a basis that is exempt from the prospectus requirements under Applicable Canadian Securities Laws;

 

(d)
the definitive form of share certificate evidencing the CSI Shares has been and will be at the Closing, duly authorized, approved
and adopted by CSI and comply with all legal requirements relating thereto.

 

SECTION
3.11. Brokers; Schedule of Fees and Expenses. No broker, investment banker, financial advisor or other person is entitled
to any broker’s, finder’s, financial advisor’s or other similar fee or commission in connection with the Transactions
based upon arrangements made by or on behalf of CSI.

 

SECTION
3.12. Contracts. There are no Contracts that are material to the business, properties, assets, condition (financial or
otherwise), results of operations or prospects of CSI taken as a whole. CSI is not in violation of or in default under (nor does
there exist any condition which upon the passage of time or the giving of notice would cause such a violation of or default under)
any Contract to which it is a party or by which it or any of its properties or assets is bound, except for violations or defaults
that would not, individually or in the aggregate, reasonably be expected to result in a CSI Material Adverse Effect.

 

SECTION
3.13. Title to Properties. Except as set forth on Schedule 3.12, CSI has sufficient title to, or valid leasehold interests
in, all of its properties and assets used in the conduct of its businesses. All such assets and properties, other than assets
and properties in which CSI has leasehold interests, are free and clear of all Liens other than those Liens that, in the aggregate,
do not and will not materially interfere with the ability of CSI to conduct business as currently conducted.

 

SECTION
3.14. Reserved.

 

SECTION
3.15. Labor Matters. There are no collective bargaining or other labor union agreements to which CSI is a party or by which
it is bound. No material labor dispute exists or, to the knowledge of CSI, is imminent with respect to any of the employees of
CSI.

 

SECTION
3.16. Investment Company. CSI is not, and is not an affiliate of, and immediately following the Closing will not have become,
an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

SECTION
3.17. Disclosure. CSI confirms that neither it nor any person acting on its behalf has provided the Company or its respective
agents or counsel with any information that CSI believes constitutes material, non-public information, except insofar as the existence
and terms of the proposed transactions hereunder may constitute such information and except for information that will be disclosed
by the Company no later than four (4) business days after the Closing. The Company understands and confirms that CSI will rely
on the foregoing representations and covenants in effecting transactions in the Exchanged Securities. All disclosure provided
to CSI regarding the Company, its business and the Transactions, furnished by or on behalf of the Company (including the Company’s
representations and warranties set forth in this Agreement) are true and correct and do not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading.

 

    	10

    	 

    

 

SECTION
3.18. Reserved.

 

SECTION
3.19. Foreign Corrupt Practices. Neither the Company, nor, to the Company’s knowledge, any officer, agent, employee
or other person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i) used any
corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity;
(ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds;
(iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made
any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government
official or employee.

 

SECTION
3.20. Transactions With Affiliates and Employees. None of the officers or directors of CSI and, to the knowledge of CSI,
none of the employees of CSI is presently a party to any transaction with CSI or any subsidiary (other than for services as employees,
officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of CSI, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee or partner.

 

SECTION
3.21. Application of Takeover Protections. CSI has taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other
similar anti-takeover provision under CSI’s charter documents or the laws of its state of incorporation that is or could
become applicable to the CSI a result of CSI fulfilling its obligations or exercising their rights under this Agreement, including,
without limitation, the issuance of the CSI Shares to the Company.

 

SECTION
3.22. Listing and Maintenance Requirements. CSI is, and has no reason to believe that it will not in the foreseeable future
continue to be, in compliance with the listing and maintenance requirements for continued trading of its shares of common stock
on the trading market on which such shares are currently listed or quoted. The issuance and sale of the CSI Shares under this
Agreement does not contravene the rules and regulations of the trading market on which CSI’s securities are currently listed
or quoted, and all approvals of the stockholders of CSI, as required for CSI to issue and deliver to the Company the CSI Shares
contemplated by this Agreement, have been obtained.

 

SECTION
3.23. Good Title. CSI has the right and authority to sell and deliver the CSI Shares as provided herein. The Company will
receive good title to such CSI Shares, free and clear of all liens, security interests, pledges, equities and claims of any kind,
voting trusts and other encumbrances (collectively, “Liens”).

 

SECTION
3.24. Power and Authority. All acts required to be taken by CSI in order to enter into this Agreement and to carry out
the Transactions as contemplated herein have been properly taken. This Agreement constitutes a legal, valid and binding obligation
of CSI, enforceable against it in accordance with the terms hereof.

 

    	11

    	 

    

 

SECTION
3.25. No Finder’s Fee. CSI has not created any obligation for any finder’s, investment banker’s or broker’s
fee in connection with the Transactions.

 

SECTION
3.26. Purchase Entirely for Own Account. The GSRX Shares proposed to be acquired by CSI hereunder will be acquired for
investment purposes, for CSI’s account, and not with a view to the resale or distribution of any part thereof, and CSI has
no present intention of selling or otherwise distributing the GSRX Shares which it will receive pursuant to this Agreement, except
in compliance with applicable securities laws.

 

SECTION
3.27. Available Information. CSI has such knowledge and experience in financial and business matters that they are capable
of evaluating the merits and risks of an investment in the GSRX Shares.

 

SECTION
3.28. Non-Registration. CSI understands that the GSRX Shares have not been registered under the Securities Act of 1933,
as amended (the “Securities Act”) and, if issued in accordance with the provisions of this Agreement, will
be issued by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other
things, the bona fide nature of the investment intent and the accuracy of the Parties’ representations as expressed herein.

 

SECTION
3.29. Restricted Securities. CSI understands that the GSRX Shares are characterized as “restricted securities”
under the Securities Act inasmuch as this Agreement contemplates that, if acquired by CSI pursuant hereto, the GSRX Shares would
be acquired in a transaction not involving a public offering. CSI further acknowledges that if the GSRX Shares are issued in accordance
with the provisions of this Agreement, such GSRX Shares may not be resold without registration under the Securities Act or the
existence of an exemption therefrom. CSI represents that it is familiar with Rule 144 promulgated under the Securities Act, as
presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 

SECTION
3.30. Legends. CSI understands that the GSRX Shares will bear the following legend or another legend that is similar to
the following:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
SECURED BY SUCH SECURITIES.

 

    	12

    	 

    

 

THESE
SECURITIES ARE SUBJECT TO A LOCKUP AGREEMENT BY AND BETWEEN GSRX INDUSRTIES INC. AND CHEMESIS INTERNATIONAL INC. EXECUTED ON THE
DATE HEREOF.

 

and
any legend required by the “blue sky” laws of any state to the extent such laws are applicable to the securities represented
by the certificate so legended.

 

SECTION
3.31. Accredited Investor. CSI is an “accredited investor” within the meaning of Rule 501 under the Securities
Act and CSI was not organized for the specific purpose of acquiring the GSRX Shares.

 

SECTION
3.32. Acknowledgment. CSI acknowledges that it has read the representations and warranties of the Company set forth in
Article II herein and such representations and warranties are, to the best of CSI’s knowledge, true and correct as of the
date hereof.

 

ARTICLE
IV

Deliveries

 

SECTION
4.01. Deliveries of CSI.

 

(a)
Concurrently herewith, CSI shall deliver to the Company, a copy of this Agreement executed by CSI.

 

(b)
Promptly following the Closing, CSI shall deliver to the Company, certificates representing the CSI Shares issued to the Company.

 

SECTION
4.02. Deliveries of the Company.

 

(a)
Concurrently herewith, the Company is delivering to CSI this Agreement executed by the Company.

 

(b)
Promptly following the Closing, the Company shall deliver to CSI, certificates representing the GSRX Shares issued to CSI.

 

ARTICLE
V

Conditions to Closing

 

SECTION
5.01. Company Conditions Precedent. The obligation of the Company to enter into and complete the Closing is subject, at
the option of the Company, to the fulfillment on or prior to the Closing Date of the following conditions:

 

(a)
Representations and Covenants. The representations and warranties of CSI contained in this Agreement shall be true in all
material respects on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date. CSI
shall have performed and complied in all material respects with all covenants and agreements required by this Agreement to be
performed or complied with by CSI on or prior to the Closing Date.

 

    	13

    	 

    

 

(b)
Litigation. No action, suit or proceeding shall have been instituted before any court or governmental or regulatory body
or instituted or threatened by any governmental or regulatory body to restrain, modify or prevent the carrying out of the Transactions
or to seek damages or a discovery order in connection with such Transactions, or which has or may have, in the reasonable opinion
of the Company, a materially adverse effect on the assets, properties, business, operations or condition (financial or otherwise)
of CSI or the Company.

 

(c)
No Material Adverse Change. There shall not have been any occurrence, event, incident, action, failure to act, or transaction
since the date as first set forth above which has had or is reasonably likely to cause a CSI Material Adverse Effect.

 

(d)
Deliveries. The deliveries specified in Section 4.01 shall have been made by CSI.

 

(e)
No Suspensions of Trading; Listing. CSI’s securities are not subject to any cease trade order and trading in CSI’s
securities shall not have been suspended by the CSE or any trading market (except for any suspensions of trading of not more than
one trading day solely to permit dissemination of material information regarding CSI) at any time since the date of execution
of this Agreement, and CSI securities shall have been at all times since such date listed for trading on a trading market.

 

(f)
Reporting Issuer Status. CSI is a reporting issuer not in default in each of British Columbia, Alberta and Ontario.

 

(g)
Prospectus Exempt. The Company and its counsel are satisfied that the CSI Shares being issued hereunder will be issued
in a manner that is exempt from the prospectus requirements under Applicable Canadian Securities Laws, acting reasonably.

 

(h)
CSE Filings. Evidence that CSI has filed all necessary documentation with the CSE in form and substance reasonably satisfactory
to the Company and its counsel.

 

SECTION
5.02. CSI Conditions Precedent. The obligations of CSI to enter into and complete the Closing are subject, at the option
of CSI, to the fulfillment on or prior to the Closing Date of the following conditions, any one or more of which may be waived
by CSI in writing.

 

(a)
Representations and Covenants. The representations and warranties of the Company contained in this Agreement shall be true
in all material respects on and as of the Closing Date with the same force and effect as though made on and as of the Closing
Date. The Company shall have performed and complied in all material respects with all covenants and agreements required by this
Agreement to be performed or complied with by the Company on or prior to the Closing Date.

 

(b)
Litigation. No action, suit or proceeding shall have been instituted before any court or governmental or regulatory body
or instituted or threatened by any governmental or regulatory body to restrain, modify or prevent the carrying out of the Transactions
or to seek damages or a discovery order in connection with such Transactions, or which has or may have, in the reasonable opinion
of CSI, a materially adverse effect on the assets, properties, business, operations or condition (financial or otherwise) of the
Company.

 

(c)
No Material Adverse Change. There shall not have been any occurrence, event, incident, action, failure to act, or transaction
since inception which has had or is reasonably likely to cause a Company Material Adverse Effect.

 

    	14

    	 

    

 

(d)
Deliveries. The deliveries specified in Section 4.02 shall have been made by the Company.

 

(e)
No Suspensions of Trading; Listing. Trading in Company’s securities shall not have been suspended by the OTCQB or
any trading market (except for any suspensions of trading of not more than one trading day solely to permit dissemination of material
information regarding the Company) at any time since the date of execution of this Agreement, and the Company’s securities
shall have been at all times since such date listed for trading on a trading market.

 

ARTICLE
VI

Covenants

 

SECTION
6.01. Public Announcements. CSI and the Company will consult with each other before issuing, and provide each other the
opportunity to review and comment upon, any press releases or other public statements with respect to the Agreement and the Transactions
and shall not issue any such press release or make any such public statement prior to such consultation, except as may be required
by applicable Law, court process or by obligations pursuant to any listing agreement with any national securities exchanges.

 

SECTION
6.02. Post-Closing Filings. Under Applicable Canadian Securities Laws CSI covenants to do all things and prepare and timely
file all documents that are required to be filed under Applicable Canadian Securities Laws as a result of the closing of the transactions
contemplated herein, and GSRX covenants to provide all information which may be required for such purposes.

 

SECTION
6.03. Fees and Expenses. All fees and expenses incurred in connection with this Agreement shall be paid by the Party incurring
such fees or expenses, whether or not this Agreement is consummated, provided that, upon Closing no payments will be due to any
party in connection with the preparation and execution of this Agreement.

 

SECTION
6.04. Continued Efforts. Each Party shall use commercially reasonable efforts to (a) take all action reasonably necessary
to consummate the Transactions, and (b) take such steps and do such acts as may be necessary to keep all of its representations
and warranties true and correct as of the Closing Date with the same effect as if the same had been made, and this Agreement had
been dated, as of the Closing Date.

 

SECTION
6.05. Exclusivity. Each of CSI and the Company shall not (and shall not cause or permit any of their affiliates to) engage
in any discussions or negotiations with any person or take any action that would be inconsistent with the Transactions and that
has the effect of avoiding the Closing contemplated hereby. Each of CSI and the Company shall notify each other immediately if
any person makes any proposal, offer, inquiry, or contact with respect to any of the foregoing.

 

SECTION
6.06. Filing of 8-K and Press Release. The Company shall file, no later than four (4) business days of the Closing Date,
a Current Report on Form 8-K and attach as exhibits all relevant agreements with the Securities and Exchange Commission disclosing
the terms of this Agreement and other requisite disclosure regarding the Transactions. Additionally, CSI shall file, no later
than four (4) business days of the Closing Date, a Material Change Report on Form 51-102F3 and attach as exhibits all relevant
agreements with the SEDAR disclosing the terms of this Agreement and other requisite disclosure regarding the Transactions.

 

    	15

    	 

    

 

ARTICLE
VII

Miscellaneous

 

SECTION
7.01. Indemnification. Each Party hereby agrees to indemnify and hold harmless the other party, its officers, directors,
employees and agents against any and all losses, claims, expenses, damages or liabilities, jointly and severally, to which any
of them may become subject or which they may incur, including all reasonable attorney’s fees and costs, to the fullest extent
lawful, and all costs and expenses arising out of or in connection with any suit, action, or claim, arising out of the breach
of their respective duties and responsibilities under this Agreement, or resulting from any breach of any representations or warranties
under this Agreement with respect to their business, operations or assets.

 

SECTION
7.02. Notices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing
and shall be deemed given upon receipt by the Parties at the following addresses (or at such other address for a Party as shall
be specified by like notice):

 

If
to CSI, to:

 

Chemesis
International Inc.

Suite
2710 – 200 Granville Street

Vancouver,
BC V6C 1S4

 

Attention:
Aman Parmar

 

with
a copy (which shall not constitute notice) to:

 

Cassels
Brock & Blackwell LLP

885
West Georgia Street, Suite 2200

Vancouver,
BCV6C 3E8

Attention:
Deepak Gill

 

If
to the Company, to:

 

GSRX
Industries Inc.

1301
E Debbie Lane 102-160

Mansfield,
TX 76063

Attention:
Tom Gingerich

 

With
a copy to:

 

Sichenzia
Ross Ference LLP

1185
Avenue of the Americas, 37th Floor

New
York, NY 10036

Attn:
Darrin M. Ocasio, Esq.

 

SECTION
7.03. Amendments; Waivers; No Additional Consideration. No provision of this Agreement may be waived or amended except
in a written instrument signed by the Company and CSI. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of
any other provision, condition or requirement hereof, nor shall any delay or omission of any Party to exercise any right hereunder
in any manner impair the exercise of any such right.

 

    	16

    	 

    

 

SECTION
7.04. Replacement of Securities. If any certificate or instrument evidencing any Exchange Security is mutilated, lost,
stolen or destroyed, the Party in which the Exchange Security represents ownership in shall issue or cause to be issued in exchange
and substitution for and upon cancellation thereof, or in lieu of and substitution therefore, a new certificate or instrument,
but only upon receipt of evidence reasonably satisfactory to the Party of such loss, theft or destruction and customary and reasonable
indemnity, if requested. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs associated with the issuance of such replacement Exchange Security. If a replacement certificate or instrument
evidencing any Exchange Securities is requested due to a mutilation thereof, each Party may require delivery of such mutilated
certificate or instrument as a condition precedent to any issuance of a replacement.

 

SECTION
7.05. Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery
of damages, CSI and the Company will be entitled to specific performance under this Agreement. The Parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing
sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at
law would be adequate.

 

SECTION
7.06. Interpretation. When a reference is made in this Agreement to a Section, such reference shall be to a Section of
this Agreement unless otherwise indicated. Whenever the words “include,” “includes” or “including”
are used in this Agreement, they shall be deemed to be followed by the words “without limitation.”

 

SECTION
7.07. Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced
by any rule or Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full
force and effect so long as the economic or legal substance of the Transactions contemplated hereby is not affected in any manner
materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of
being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the
Parties as closely as possible in an acceptable manner to the end that Transactions contemplated hereby are fulfilled to the extent
possible.

 

SECTION
7.08. Counterparts; Facsimile Execution. This Agreement may be executed in one or more counterparts, all of which shall
be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of
the Parties and delivered to the other Parties. Facsimile execution and delivery of this Agreement is legal, valid and binding
for all purposes.

 

SECTION
7.09. Entire Agreement; Third Party Beneficiaries. This Agreement, and the ancillary rights agreement between the parties
of even date, (a) constitutes the entire agreement, and supersede all prior agreements and understandings, both written and oral,
among the Parties with respect to the Transactions and (b) is not intended to confer upon any person other than the Parties any
rights or remedies.

 

SECTION
7.10. Governing Law. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State
of New York, without reference to principles of conflicts of laws. Any action or proceeding brought for the purpose of enforcement
of any term or provision of this Agreement shall be brought only in the Federal or state courts sitting in the State of New York
and the parties hereby waive any and all rights to trial by jury.

 

SECTION
7.11. Assignment. Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be
assigned, in whole or in part, by operation of law or otherwise by any of the Parties without the prior written consent of the
other Parties. Any purported assignment without such consent shall be void. Subject to the preceding sentences, this Agreement
will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and assigns.

 

[Signature
Page Follows]

 

    	17

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed and delivered this Share Exchange Agreement as of the date first above written.

 

CSI:

 

	 	Chemesis International
Inc.
	 	 
	 	By:	 
	 	Name:	               
	 	Title:	 

 

[Company
Signature Pages Follow

 

    	18

    	 

    

 

The
Company:

 

	 	GSRX INDUSTRIES INC.
	 	 
	 	By:	 
	 	Name:	Leslie
Ball
	 	Title:	Chief Executive Officer

 

[Signature
Page to Share Exchange Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]